Pancreatic cancer early detection: Expanding higher-risk group with clinical and metabolomics parameters

World Journal of Gastroenterology

Volumn 21, Issue 6, 2015, Pages 1707-1717

  Urayama, Shiro ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Early detection; Endoscopic ultrasound; Metabolomics; Pancreatic cancer

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER; TUMOR MARKER;

ANGIOGRAPHY; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; DEVELOPED COUNTRY; DIAGNOSTIC ACCURACY; DISEASE MARKER; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; FAMILIAL CANCER; FINE NEEDLE ASPIRATION BIOPSY; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; METABOLOMICS; MULTIDETECTOR COMPUTED TOMOGRAPHY; MUTATION RATE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; SCREENING TEST; ULTRASOUND; CARCINOMA, PANCREATIC DUCTAL; EARLY CANCER DIAGNOSIS; ECHOGRAPHY; ENDOSCOPIC ULTRASONOGRAPHY; GENETICS; METABOLISM; MOLECULAR DIAGNOSIS; PANCREATIC NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; EARLY DETECTION OF CANCER; ENDOSONOGRAPHY; HUMANS; METABOLOMICS; MOLECULAR DIAGNOSTIC TECHNIQUES; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84922700243     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i6.1707     Document Type: Article

References (126)

1. National Cancer Institute. Cancer topics: Pancreatic cancer. Available from: URL: http://www.cancer.gov/cancertopics/types/pancreatic
2. American Cancer Society. Cancer Facts & Figures, 2014. Available from: URL: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
4. Beger HG, Rau B, Gansauge F, Poch B, Link KH. Treatment of pancreatic cancer: challenge of the facts. World J Surg 2003; 27: 1075-1084 [PMID: 12925907 DOI: 10.1007/s00268-003-7165-7]
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249 [PMID: 19474385 DOI: 10.3322/caac.20006]
6. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-2921 [PMID: 24840647 DOI: 10.1158/0008-5472]
7. Ahmad NA, Lewis JD, Ginsberg GG, Haller DG, Morris JB, Williams NN, Rosato EF, Kochman ML. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol 2001; 96: 2609-2615 [PMID: 11569683 DOI: 10.1111/j.1572-0241.2001.04123.x]
8. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, Madura JA, Wiebke EA, Lillemoe KD. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006; 10: 1338-1345; discussion 1345-1346 [PMID: 17175452 DOI: 10.1016/j.gassur.2006.09.008]
9. Egawa S, Takeda K, Fukuyama S, Motoi F, Sunamura M, Matsuno S. Clinicopathological aspects of small pancreatic cancer. Pancreas 2004; 28: 235-240 [PMID: 15084963 DOI: 10.1097/00006676-200404000-00004]
10. Ariyama J, Suyama M, Ogawa K, Ikari T. [Screening of pancreatic neoplasms and the diagnostic rate of small pancreatic neoplasms]. Nihon Rinsho 1986; 44: 1729-1734 [PMID: 3537369]
11. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117 [PMID: 20981102 DOI: 10.1038/nature09515]
12. Rösch T, Braig C, Gain T, Feuerbach S, Siewert JR, Schusdziarra V, Classen M. Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography. Gastroenterology 1992; 102: 188-199 [PMID: 1727753]
13. Müller MF, Meyenberger C, Bertschinger P, Schaer R, Marincek B. Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging. Radiology 1994; 190: 745-751 [PMID: 8115622 DOI: 10.1148/radiology.190.3.8115622]
14. Agarwal B, Abu-Hamda E, Molke KL, Correa AM, Ho L. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 2004; 99: 844-850 [PMID: 15128348 DOI: 10.1111/j.1572-0241.2004.04177.x]
15. Yasuda K, Mukai H, Fujimoto S, Nakajima M, Kawai K. The diagnosis of pancreatic cancer by endoscopic ultrasonography. Gastrointest Endosc 1988; 34: 1-8 [PMID: 3280392 DOI: 10.1016/S0016-5107(88)71220-1]
16. Rösch T, Lorenz R, Braig C, Feuerbach S, Siewert JR, Schusdziarra V, Classen M. Endoscopic ultrasound in pancreatic tumor diagnosis. Gastrointest Endosc 1991; 37: 347-352 [PMID: 2070987 DOI: 10.1016/S0016-5107(91)70729-3]
17. DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, Ciaccia D, Lane KA, Maglinte D, Kopecky K, LeBlanc J, McHenry L, Madura J, Aisen A, Cramer H, Cummings O, Sherman S. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004; 141: 753-763 [PMID: 15545675 DOI: 10.7326/0003-4819-141-10-200411160-00006]
18. Khashab MA, Yong E, Lennon AM, Shin EJ, Amateau S, Hruban RH, Olino K, Giday S, Fishman EK, Wolfgang CL, Edil BH, Makary M, Canto MI. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011; 73: 691-696 [PMID: 21067742 DOI: 10.1016/j.gie.2010.08.030]
19. Vilmann P, Jacobsen GK, Henriksen FW, Hancke S. Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease. Gastrointest Endosc 1992; 38: 172-173 [PMID: 1568614 DOI: 10.1016/S0016-5107(92)70385-X]
20. Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc 2012; 75: 319-331 [PMID: 22248600 DOI: 10.1016/j.gie.2011.08.049]
21. Hébert-Magee S, Bae S, Varadarajulu S, Ramesh J, Frost AR, Eloubeidi MA, Eltoum IA. The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma: a meta-analysis. Cytopathology 2013; 24: 159-171 [PMID: 23711182 DOI: 10.1111/cyt.12071]
22. Luz LP, Al-Haddad MA, Sey MS, DeWitt JM. Applications of endoscopic ultrasound in pancreatic cancer. World J Gastroenterol 2014; 20: 7808-7818 [PMID: 24976719 DOI: 10.3748/wjg.v20.i24.7808]
23. Fritscher-Ravens A, Izbicki JR, Sriram PV, Krause C, Knoefel WT, Topalidis T, Jaeckle S, Thonke F, Soehendra N. Endosonography-guided, fine-needle aspiration cytology extending the indication for organ-preserving pancreatic surgery. Am J Gastroenterol 2000; 95: 2255-2260 [PMID: 11007226 DOI: 10.1111/j.1572-0241.2000.02311.x]
24. Pellisé M, Castells A, Ginès A, Solé M, Mora J, Castellví-Bel S, Rodríguez-Moranta F, Fernàndez-Esparrach G, Llach J, Bordas JM, Navarro S, Piqué JM. Clinical usefulness of KRAS mutational analysis in the diagnosis of pancreatic adenocarcinoma by means of endosonography-guided fine-needle aspiration biopsy. Aliment Pharmacol Ther 2003; 17: 1299-1307 [PMID: 12755843 DOI: 10.1046/j.1365-2036.2003.01579.x]
25. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol 2005; 23: 4524-4531 [PMID: 16002843 DOI: 10.1200/JCO.2005.19.711]
26. Takahashi K, Yamao K, Okubo K, Sawaki A, Mizuno N, Ashida R, Koshikawa T, Ueyama Y, Kasugai K, Hase S, Kakumu S. Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointest Endosc 2005; 61: 76-79 [PMID: 15672060 DOI: 10.1016/S0016-5107(04)02224-2]
27. Maluf-Filho F, Kumar A, Gerhardt R, Kubrusly M, Sakai P, Hondo F, Matuguma SE, Artifon E, Monteiro da Cunha JE, César Machado MC, Ishioka S, Forero E. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass. J Clin Gastroenterol 2007; 41: 906-910 [PMID: 18090159 DOI: 10.1097/mcg.0b013e31805905e9]
28. Bournet B, Souque A, Senesse P, Assenat E, Barthet M, Lesavre N, Aubert A, O'Toole D, Hammel P, Levy P, Ruszniewski P, Bouisson M, Escourrou J, Cordelier P, Buscail L. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. Endoscopy 2009; 41: 552-557 [PMID: 19533561 DOI: 10.1055/s-0029-1214717]
29. Tada M, Komatsu Y, Kawabe T, Sasahira N, Isayama H, Toda N, Shiratori Y, Omata M. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 2002; 97: 2263-2270 [PMID: 12358243 DOI: 10.1111/j.1572-0241.2002.05980.x]
30. Itoi T, Takei K, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, Nakamura K, Moriyasu F, Tsuchida A, Kasuya K. Immunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses. Oncol Rep 2005; 13: 229-234 [PMID: 15643503 DOI: 10.3892/or.13.2.229]
31. Mishra G, Zhao Y, Sweeney J, Pineau BC, Case D, Ho C, Blackstock AW, Geisinger K, Howerton R, Levine E, Shen P, Ibdah J. Determination of qualitative telomerase activity as an adjunct to the diagnosis of pancreatic adenocarcinoma by EUS-guided fine-needle aspiration. Gastrointest Endosc 2006; 63: 648-654 [PMID: 16564867 DOI: 10.1016/j.gie.2005.11.056]
32. Salek C, Benesova L, Zavoral M, Nosek V, Kasperova L, Ryska M, Strnad R, Traboulsi E, Minarik M. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 2007; 13: 3714-3720 [PMID: 17659731 DOI: 10.3748/wjg.v13.i27.3714]
33. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009; 133: 365-374 [PMID: 19260742 DOI: 10.1043/1543-2165-133.3.365]
34. Permuth-Wey J, Egan KM. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 2009; 8: 109-117 [PMID: 18763055 DOI: 10.1007/s10689-008-9214-8]
35. Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007; 25: 1417-1422 [PMID: 17416862 DOI: 10.1200/JCO.2006.09.2452]
36. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Griffin C, Cameron JL, Yeo CJ, Kern S, Hruban RH. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64: 2634-2638 [PMID: 15059921 DOI: 10.1158/0008-5472.CAN-03-3823]
37. Wang L, Brune KA, Visvanathan K, Laheru D, Herman J, Wolfgang C, Schulick R, Cameron JL, Goggins M, Hruban RH, Klein AP. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2829-2834 [PMID: 19843679 DOI: 10.1158/1055-9965.EPI-09-0557]
38. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453 [PMID: 11113065 DOI: 10.1053/gast.2000.20228]
39. Rebours V, Boutron-Ruault MC, Schnee M, Férec C, Maire F, Hammel P, Ruszniewski P, Lévy P. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol 2008; 103: 111-119 [PMID: 18184119 DOI: 10.1111/j.1572-0241.2007.01597.x]
40. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK, Perrault J, Whitcomb DC. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89: 442-446 [PMID: 9091646 DOI: 10.1093/jnci/89.6.442]
41. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010; 24: 349-358 [PMID: 20510834 DOI: 10.1016/j.bpg.2010.02.007]
42. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333: 970-974 [PMID: 7666916 DOI: 10.1056/NEJM199510123331504]
43. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995; 333: 975-977 [PMID: 7666917 DOI: 10.1056/NEJM199510123331505]
44. Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog 2012; 51: 14-24 [PMID: 22162228 DOI: 10.1002/mc.20855]
45. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, van't Veer LJ, Rookus MA, van Leeuwen FE. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42: 711-719 [PMID: 16141007 DOI: 10.1136/jmg.2004.028829]
46. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94: 1365-1372 [PMID: 12237282 DOI: 10.1093/jnci/94.18.1365]
47. Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M, Rothenmund H, Gallinger S, Klein A, Petersen GM, Hruban RH. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 342-346 [PMID: 17301269 DOI: 10.1158/1055-9965.EPI-06-0783]
48. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56: 5360-5364 [PMID: 8968085]
49. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grützmann R, Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP, Bartsch DK. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95: 214-221 [PMID: 12569143 DOI: 10.1093/jnci/95.3.214]
50. Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, Redston M, Gallinger S. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000; 60: 409-416 [PMID: 10667595]
51. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH, Kern SE. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62: 3789-3793 [PMID: 12097290]
52. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB, Syngal S. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009; 302: 1790-1795 [PMID: 19861671 DOI: 10.1001/jama.2009.1529]
53. McWilliams R, Highsmith WE, Rabe KG, de Andrade M, Tordsen LA, Holtegaard LM, Petersen GM. Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. Gut 2005; 54: 1661-1662 [PMID: 16227367 DOI: 10.1136/gut.2005.074534]
54. Greenhalf W, Grocock C, Harcus M, Neoptolemos J. Screening of high-risk families for pancreatic cancer. Pancreatology 2009; 9: 215-222 [PMID: 19349734 DOI: 10.1159/000210262]
55. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, Brentnall TA, Lynch HT, Canto MI. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007; 56: 1460-1469 [PMID: 17872573 DOI: 10.1136/gut.2006.108456]
56. Lynch HT, Deters CA, Snyder CL, Lynch JF, Villeneuve P, Silberstein J, Martin H, Narod SA, Brand RE. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 2005; 158: 119-125 [PMID: 15796958 DOI: 10.1016/j.cancergencyto.2004.01.032]
57. Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Dowen S, Otey CA, Crispin DA, George RD, Whitcomb DC, Brentnall TA. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 2006; 3: e516 [PMID: 17194196 DOI: 10.1371/journal.pmed.0030516]
58. Earl J, Yan L, Vitone LJ, Risk J, Kemp SJ, McFaul C, Neoptolemos JP, Greenhalf W, Kress R, Sina-Frey M, Hahn SA, Rieder H, Bartsch DK. Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1948-1955 [PMID: 17035404 DOI: 10.1158/1055-9965.EPI-06-0376]
59. Zervos EE, Tanner SM, Osborne DA, Bloomston M, Rosemurgy AS, Ellison EC, Melvin WS, de la Chapelle A. Differential gene expression in patients genetically predisposed to pancreatic cancer. J Surg Res 2006; 135: 317-322 [PMID: 16815451 DOI: 10.1016/j.jss.2006.03.022]
60. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217 [PMID: 19264984 DOI: 10.1126/science.1171202]
61. Brune KA, Lau B, Palmisano E, Canto M, Goggins MG, Hruban RH, Klein AP. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 2010; 102: 119-126 [PMID: 20068195 DOI: 10.1093/jnci/djp466]
62. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003; 124: 1292-1299 [PMID: 12730869 DOI: 10.1016/S0016-5085(03)00272-5]
63. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19: 182-186 [PMID: 14731128 DOI: 10.1111/j.1440-1746.2004.03219.x]
64. Bussom S, Saif MW. Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP 2010; 11: 128-130 [PMID: 20208319]
65. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005; 294: 2872-2878 [PMID: 16352795 DOI: 10.1001/jama.294.22.2872]
66. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, Ali SZ, Jagannath S, Petersen GM, Fishman EK, Piantadosi S, Giardiello FM, Hruban RH. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-621 [PMID: 15224285 DOI: 10.1016/S1542-3565(04)00244-7]
67. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, Fishman EK, Brune K, Axilbund J, Griffin C, Ali S, Richman J, Jagannath S, Kantsevoy SV, Kalloo AN. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4: 766-81; quiz 665 [PMID: 16682259 DOI: 10.1016/j.cgh.2006.02.005]
68. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, Takahashi N, Fletcher J, Petersen G, Klein AP, Axilbund J, Griffin C, Syngal S, Saltzman JR, Mortele KJ, Lee J, Tamm E, Vikram R, Bhosale P, Margolis D, Farrell J, Goggins M. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012; 142: 796-804; quiz e14-5 [PMID: 22245846 DOI: 10.1053/j.gastro.2012.01.005]
69. Kimmey MB, Bronner MP, Byrd DR, Brentnall TA. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002; 56: S82-S86 [PMID: 12297755 DOI: 10.1016/S0016-5107(02)70092-8]
70. Carlson C, Greenhalf W, Brentnall TA. Screening of hereditary pancreatic cancer families. In: Berger HG, Bucher M, Kozarek R, Lerch M, Neoptolemos J, Warshaw A, Whitcomb D, Shiratori K, editors. The Pancreas: An Integrated Textbook of Basic Science, Medicine and Surgery. Second Edition. Oxford UK: Wiley-Blackwell Publishing, 2008: 636-642 [DOI: 10.1002/9781444300123.ch64]
71. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Heverhagen JT, Gress TM, Rothmund M, Bartsch DK. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009; 58: 1410-1418 [PMID: 19470496 DOI: 10.1136/gut.2008.171611]
72. Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, Kuipers EJ, Nio Y, Fockens P, Bruno MJ. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009; 104: 2175-2181 [PMID: 19491823 DOI: 10.1038/ajg.2009.276]
73. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-347 [PMID: 23135763 DOI: 10.1136/gutjnl-2012-303108]
74. Lennon AM, Wolfgang CL, Canto MI, Klein AP, Herman JM, Goggins M, Fishman EK, Kamel I, Weiss MJ, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Hruban RH. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res 2014; 74: 3381-3389 [PMID: 24924775 DOI: 10.1158/0008-5472.CAN-14-0734]
75. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134: 95-101 [PMID: 18061176 DOI: 10.1053/j.gastro.2007.10.040]
76. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129: 504-511 [PMID: 16083707 DOI: 10.1016/j.gastro.2005.05.007]
77. Ogawa Y, Tanaka M, Inoue K, Yamaguchi K, Chijiiwa K, Mizumoto K, Tsutsu N, Nakamura Y. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 2002; 94: 2344-2349 [PMID: 12015758 DOI: 10.1002/cncr.10493]
78. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009; 10: 88-95 [PMID: 19111249 DOI: 10.1016/S1470-2045(08)70337-1]
79. Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. Mol Cancer 2003; 2: 4 [PMID: 12556242 DOI: 10.1186/1476-4598-2-4]
80. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andrén-Sandberg A, Domellöf L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328: 1433-1437 [PMID: 8479461 DOI: 10.1056/NEJM199305203282001]
81. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB, Fuchs CS, Gross MD, Jacobs EJ, Lacroix AZ, Petersen GM, Stolzenberg-Solomon RZ, Zheng W, Albanes D, Amundadottir L, Bamlet WR, Barricarte A, Bingham SA, Boeing H, Boutron-Ruault MC, Buring JE, Chanock SJ, Clipp S, Gaziano JM, Giovannucci EL, Hankinson SE, Hartge P, Hoover RN, Hunter DJ, Hutchinson A, Jacobs KB, Kraft P, Lynch SM, Manjer J, Manson JE, McTiernan A, McWilliams RR, Mendelsohn JB, Michaud DS, Palli D, Rohan TE, Slimani N, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Virtamo J, Wolpin BM, Yu K, Zeleniuch-Jacquotte A, Patel AV. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 2010; 170: 791-802 [PMID: 20458087 DOI: 10.1001/archinternmed.2010.63]
82. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009; 301: 2553-2562 [PMID: 19549972 DOI: 10.1001/jama.2009.886]
83. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591 [PMID: 15286738 DOI: 10.1038/nrc1408]
84. Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 2005; 93: 1062-1067 [PMID: 16234822 DOI: 10.1038/sj.bjc.6602819]
85. Larsson SC, Permert J, Hakånsson N, Näslund I, Bergkvist L, Wolk A. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J Cancer 2005; 93: 1310-1315 [PMID: 16288300 DOI: 10.1038/sj.bjc.6602868]
86. Dawson DW, Hertzer K, Moro A, Donald G, Chang HH, Go VL, Pandol SJ, Lugea A, Gukovskaya AS, Li G, Hines OJ, Rozengurt E, Eibl G. High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila) 2013; 6: 1064-1073 [PMID: 23943783 DOI: 10.1158/1940-6207.CAPR-13-0065]
87. Philip B, Roland CL, Daniluk J, Liu Y, Chatterjee D, Gomez SB, Ji B, Huang H, Wang H, Fleming JB, Logsdon CD, Cruz-Monserrate Z. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 2013; 145: 1449-1458 [PMID: 23958541 DOI: 10.1053/j.gastro.2013.08.018]
88. Oliver SG. Functional genomics: lessons from yeast. Philos Trans R Soc Lond B Biol Sci 2002; 357: 17-23 [PMID: 11839178 DOI: 10.1098/rstb.2001.1049]
89. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst 2004; 96: 1805-1806 [PMID: 15601632 DOI: 10.1093/jnci/96.24.1805]
90. De Berardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20 [PMID: 18177721 DOI: 10.1016/j.cmet.2007.10.002]
91. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009; 15: 431-440 [PMID: 19147747 DOI: 10.1158/1078-0432.CCR-08-1059]
92. Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T, Chen CS. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Carcinogenesis 2014; 35: 2203-2213 [PMID: 24879635 DOI: 10.1093/carcin/bgu124]
93. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314 [PMID: 13298683 DOI: 10.1126/science.123.3191.309]
94. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64: 3892-3899 [PMID: 15172999 DOI: 10.1158/0008-5472.CAN-03-2904]
95. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3: 187-197 [PMID: 16517406 DOI: 10.1016/j.cmet.2006.01.012]
96. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-185 [PMID: 16517405 DOI: 10.1016/j.cmet.2006.02.002]
97. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008; 283: 28106-28114 [PMID: 18718909 DOI: 10.1074/jbc.M803508200]
98. Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 1997; 272: 22776-22780 [PMID: 9278438 DOI: 10.1074/jbc.272.36.22776]
99. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. p53 regulates mitochondrial respiration. Science 2006; 312: 1650-1653 [PMID: 16728594 DOI: 10.1126/science.1126863]
100. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-120 [PMID: 16839880 DOI: 10.1016/j.cell.2006.05.036]
101. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65: 177-185 [PMID: 15665293]
102. Britton D, Zen Y, Quaglia A, Selzer S, Mitra V, Lößner C, Jung S, Böhm G, Schmid P, Prefot P, Hoehle C, Koncarevic S, Gee J, Nicholson R, Ward M, Castellano L, Stebbing J, Zucht HD, Sarker D, Heaton N, Pike I. Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 2014; 9: e90948 [PMID: 24670416 DOI: 10.1371/journal.pone.0090948]
103. Qin Y, Zhu W, Xu W, Zhang B, Shi S, Ji S, Liu J, Long J, Liu C, Liu L, Xu J, Yu X. LSD1 sustains pancreatic cancer growth via maintaining HIF1α-dependent glycolytic process. Cancer Lett 2014; 347: 225-232 [PMID: 24561118 DOI: 10.1016/j.canlet.2014.02.013]
104. Chien W, Lee DH, Zheng Y, Wuensche P, Alvarez R, Wen DL, Aribi AM, Thean SM, Doan NB, Said JW, Koeffler HP. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol Carcinog 2014; 53: 722-735 [PMID: 23475695 DOI: 10.1002/mc.22024]
105. Kitamoto S, Yokoyama S, Higashi M, Yamada N, Matsubara S, Takao S, Batra SK, Yonezawa S. Expression of MUC17 is regulated by HIF1α-mediated hypoxic responses and requires a methylation-free hypoxia responsible element in pancreatic cancer. PLoS One 2012; 7: e44108 [PMID: 22970168 DOI: 10.1371/journal.pone.0044108]
106. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7: 77-85 [PMID: 15652751 DOI: 10.1016/j.ccr.2004.11.022]
107. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8: 143-153 [PMID: 16098467 DOI: 10.1016/j.ccr.2005.06.017]
108. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006; 25: 4675-4682 [PMID: 16892081 DOI: 10.1038/sj.onc.1209594]
109. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IP. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14: 2231-2239 [PMID: 15987702 DOI: 10.1093/hmg/ddi227]
110. MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, Watson DG, Gottlieb E. Cell-permeating alphaketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol 2007; 27: 3282-3289 [PMID: 17325041 DOI: 10.1128/MCB.01927-06]
111. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-19350 [PMID: 18032601 DOI: 10.1073/pnas.0709747104]
112. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51-56 [PMID: 18046334 DOI: 10.1038/nrc2274]
113. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010; 70: 859-862 [PMID: 20086171 DOI: 10.1158/0008-5472.CAN-09-3556]
114. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233 [PMID: 18337823 DOI: 10.1038/nature06734]
115. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033 [PMID: 19460998 DOI: 10.1126/science.1160809]
116. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, Yang X. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011; 13: 310-316 [PMID: 21336310 DOI: 10.1038/ncb2172]
117. Denkert C, Bucher E, Hilvo M, Salek R, Orešič M, Griffin J, Brockmöller S, Klauschen F, Loibl S, Barupal DK, Budczies J, Iljin K, Nekljudova V, Fiehn O. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med 2012; 4: 37 [PMID: 22546809 DOI: 10.1186/gm336]
118. Vermeersch KA, Styczynski MP. Applications of metabolomics in cancer research. J Carcinog 2013; 12: 9 [PMID: 23858297 DOI: 10.4103/1477-3163.113622]
119. Zhou W, Capello M, Fredolini C, Racanicchi L, Piemonti L, Liotta LA, Novelli F, Petricoin EF. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res 2012; 11: 554-563 [PMID: 22050456 DOI: 10.1021/pr2009274]
120. Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom 2010; 24: 613-620 [PMID: 20143319 DOI: 10.1002/rcm.4420]
121. Bathe OF, Shaykhutdinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, Dixon E, Dunse N, Sotiropoulos D, Vogel HJ. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev 2011; 20: 140-147 [PMID: 21098649 DOI: 10.1158/1055-9965.EPI-10-0712]
122. Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A, Izumi Y, Tsumura H, Tsuda M, Nishisaki H, Hayashi N, Kawano S, Fujiwara Y, Minami H, Takenawa T, Azuma T, Yoshida M. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2013; 22: 571-579 [PMID: 23542803 DOI: 10.1158/1055-9965.EPI-12-1033]
123. Ritchie SA, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, Monden M, Doki Y, Mori M, Jin W, Sajobi TT, Jayasinghe D, Chitou B, Yamazaki Y, White T, Goodenowe DB. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer 2013; 13: 416 [PMID: 24024929 DOI: 10.1186/1471-2407-13-416]
124. Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, Hanna N, Alexander HR, Hussain SP. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res 2013; 19: 4983-4993 [PMID: 23918603 DOI: 10.1158/1078-0432.CCR-13-0209]
125. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012; 336: 1040-1044 [PMID: 22628656 DOI: 10.1126/science.1218595]
126. ter Kuile BH, Westerhoff HV. Transcriptome meets metabolome: hierarchical and metabolic regulation of the glycolytic pathway. FEBS Lett 2001; 500: 169-171 [PMID: 11445079 DOI: 10.1016/S0014-5793(01)02613-8]